Gene Fusion Testing Market Size Forecast to US$ 2.5 Billion by 2035 with a Focus on Precision Oncology and Targeted Diagnostics – Analysis by Transparency Market Research

The global gene fusion testing market is expected to witness robust growth over the forecast period as precision oncology continues to transform cancer diagnosis and treatment. According to the latest market analysis, the Global Gene Fusion Testing Market was valued at US$ 0.7 Billion in 2024 and is projected to reach US$ 2.5 Billion by 2035, expanding at a CAGR of 12.1% from 2025 to 2035.

Gene fusion testing plays a vital role in detecting chromosomal rearrangements and fusion genes associated with various cancers, enabling clinicians to select targeted therapies and improve patient outcomes. Growing adoption of next-generation sequencing (NGS), increasing biomarker testing, and expanding applications in precision medicine are expected to fuel long-term market growth.

👉 Request a Sample PDF of this Strategic Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86836

Leading Companies Operating in the Market

The global gene fusion testing market remains highly competitive, with leading companies focusing on molecular diagnostic innovations, strategic collaborations, regulatory approvals, and expansion of precision oncology testing portfolios.

Major companies operating in the market include:

• Amoy Diagnostics Co., Ltd.
• ArcherDX (Integrated DNA Technologies, Inc.)
• Biocartis
• Biocare Medical, LLC
• F. Hoffmann-La Roche Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

These companies continue to invest in advanced genomic technologies, companion diagnostics, AI-driven data analysis, and global commercialization strategies to strengthen their market positions.

Rising Cancer Burden Driving Demand for Gene Fusion Testing

The increasing incidence of cancer worldwide is significantly boosting demand for accurate molecular diagnostic tests capable of identifying actionable genetic alterations.

Gene fusion testing has become an essential component of precision oncology by enabling the identification of clinically relevant gene fusions across lung cancer, leukemia, sarcoma, thyroid cancer, and several other malignancies. The growing availability of targeted therapies further supports widespread adoption of these diagnostic tests.

Personalized Medicine Accelerating Market Expansion

Healthcare systems are increasingly embracing personalized treatment approaches that rely on comprehensive genomic profiling to optimize therapeutic outcomes.

Key Growth Drivers Include:

• Rising global cancer incidence
• Growing adoption of personalized medicine
• Increasing use of companion diagnostics
• Rapid advancements in next-generation sequencing technologies
• Expanding investments in precision oncology
• Rising awareness of biomarker-based treatment selection

These trends are encouraging healthcare providers to integrate gene fusion testing into routine cancer diagnosis and treatment planning.

Technological Innovations Transforming the Industry

Manufacturers are continuously investing in advanced molecular diagnostic technologies to improve testing accuracy, turnaround time, and clinical utility.

Key Innovation Trends Include:

• Next-generation sequencing (NGS)-based testing
• Multiplex molecular diagnostic assays
• Liquid biopsy-based gene fusion detection
• AI-assisted genomic data interpretation
• High-throughput automated laboratory platforms
• Companion diagnostic assay development
• Comprehensive genomic profiling solutions

These innovations are improving diagnostic precision while enabling faster and more personalized treatment decisions.

Why Investors Are Watching This Market

The gene fusion testing market presents compelling investment opportunities as precision medicine and genomic diagnostics become central to modern healthcare.

Key Investment Drivers:

• Strong long-term growth outlook through 2035
• Rising demand for precision oncology diagnostics
• Increasing adoption of companion diagnostics
• Continuous innovation in genomic sequencing technologies
• Expanding investments in cancer research
• Growing regulatory support for molecular diagnostics

As targeted therapies become increasingly prevalent, demand for accurate gene fusion testing solutions is expected to accelerate globally.

👉 Request your Sample Research Report today and make your next strategic decision with confidence- https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86836

Significant Opportunities for Manufacturers

Manufacturers are well-positioned to capitalize on increasing demand for advanced molecular diagnostics and precision medicine solutions.

Strategic Growth Opportunities:

• Development of advanced NGS-based testing platforms
• Expansion of liquid biopsy diagnostic solutions
• Investment in AI-powered genomic analytics
• Geographic expansion into emerging healthcare markets
• Strategic collaborations with pharmaceutical companies
• Strengthening companion diagnostic portfolios

Companies focusing on innovation, automation, and precision diagnostics are expected to gain a competitive advantage during the forecast period.

Expanding Revenue Potential Across Healthcare and Diagnostics

The growing adoption of gene fusion testing is creating substantial opportunities for diagnostic laboratories, biotechnology companies, hospitals, cancer centers, and pharmaceutical manufacturers.

Key Benefits Across the Value Chain:

• Rising demand for oncology diagnostic testing
• Expansion of precision medicine programs
• Increasing adoption of companion diagnostics
• Growing utilization of genomic sequencing technologies
• Higher investment in cancer biomarker research
• Strong opportunities through laboratory automation

The combination of precision medicine, technological innovation, and expanding cancer diagnostics is expected to drive sustained market growth.

Purchase the Report to Support Strategic Business Decisions

Organizations across the healthcare value chain can leverage the report to:

• Identify high-growth market segments
• Develop expansion and investment strategies
• Benchmark competitors and industry leaders
• Evaluate partnership and acquisition opportunities
• Optimize product development and commercialization plans
• Support long-term strategic planning initiatives

Purchase the complete Gene Fusion Testing Market Report today and gain actionable intelligence to stay ahead in the rapidly evolving molecular diagnostics industry.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86836<ype=S

Actionable Insights for Business Decision-Makers

Business leaders across the molecular diagnostics ecosystem are increasingly focusing on innovation, precision medicine, and genomic technologies to strengthen their market positions.

Critical Areas of Focus:

✔ Precision oncology and biomarker testing

✔ Next-generation sequencing innovation

✔ Companion diagnostic development

✔ AI-driven genomic analysis

✔ Strategic partnerships and acquisitions

✔ Regional market expansion initiatives

Organizations that proactively invest in advanced molecular diagnostics, genomic sequencing technologies, and personalized healthcare solutions will be well-positioned to capture future growth opportunities within the global gene fusion testing market.

Explore Latest Research Reports by Transparency Market Research

➤ In Vitro Diagnostics Market

➤ Orthopedic Biomaterials Market

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Media Inquiries: media@transparencymarketresearch.com

Sales Inquiries: sales@transparencymarketresearch.com